Table 1.
The diagnostic efficiency of TrxR, CA19-9, CEA , AFP and their combinations in distinguishing PLC patients from healthy controls.
| Tumor markers | PLC patients before clinical intervention | ||||||
|---|---|---|---|---|---|---|---|
| AUC (95%CI) | SEN% | SPE% | PPV% | NPV% | PLR | NLR | |
| PLC patients vs. healthy controls | |||||||
| TrxR | 0.939 (0.915–0.964) | 92.31 | 81.33 | 83.18 | 91.36 | 4.95 | 10.57 |
| AFP | 0.677 (0.618–0.735) | 86.26 | 45.33 | 61.21 | 76.75 | 1.58 | 3.30 |
| CEA | 0.838 (0.797–0.879) | 74.73 | 75.33 | 75.18 | 74.88 | 3.03 | 2.98 |
| CA19-9 | 0.598 (0.537–0.658) | 34.62 | 87.33 | 73.21 | 57.19 | 2.73 | 1.34 |
| CEA + CA19-9 + AFP | 0.887 (0.853–0.920) | 68.13 | 92.00 | 89.49 | 74.27 | 8.52 | 2.89 |
| CEA + CA19-9 + AFP + TrxR | 0.984 (0.974–0.994) | 94.51 | 93.33 | 93.41 | 94.44 | 14.18 | 16.99 |
SPE: specificity; SEN: sensitivity; NPV: negative predictive value; PPV: positive predictive value;NLR: negative likelihood ratio. PLR: positive likelihood ratio; the diagnosic threshold of TrxR activity was 3.85 U/mL.